Patisiran Wins Two Firsts With FDA Approval | IUK Med Online
Tuesday, August 21, 2018
Home Medical News Patisiran Wins Two Firsts With FDA Approval

Patisiran Wins Two Firsts With FDA Approval

9
0
SHARE


Medpage Today

Patisiran Wins Two Firsts With FDA Approval

RNAi drug OK’d to treat polyneuropathy from hereditary transthyretin amyloidosis

MedpageToday

  • by Managing Editor, MedPage Today

WASHINGTON — The FDA said Friday it had approved patisiran (Onpattro) to treat polyneuropathy associated with hereditary transthyretin (hATTR) amyloidosis, caused by a gene mutation that leads to amyloid deposits in nerves and tissues.

Not only is patisiran the first drug with this indication, it’s also the first so-called RNA interference (RNAi) agent to win approval for any condition, the FDA noted.

Formerly known as familial amyloid polyneuropathy, hATTR amyloidosis is a rapidly progressive disease caused by a mutation in the TTR gene that results in the buildup of misfolded transthyretin protein, leading to amyloid deposits in the heart, gastrointestinal tract, and peripheral nerves. Life expectancy of patients is about 3 to 15 years after the onset of neuropathy, less in patients who have cardiomyopathy.

In the phase III APOLLO trial, patisiran slowed peripheral neuropathy progression in patients with hATTR amyloidosis, improving neurological impairment and clinical manifestations by over 18 months.

In that trial, involving 225 patients, those “who received Onpattro had better outcomes on measures of polyneuropathy including muscle strength, sensation (pain, temperature, numbness), reflexes and autonomic symptoms (blood pressure, heart rate, digestion) compared to those receiving the placebo infusions,” the FDA noted in its approval announcement. “Onpattro-treated patients also scored better on assessments of walking, nutritional status, and the ability to perform activities of daily living.”

Adverse effects seen in the clinical studies included infusion-related reactions, back pain, nausea, abdominal pain, dyspnea, and headache, the FDA said. All patients in the trials were pretreated with acetaminophen, antihistamines, and a corticosteroid to minimize infusion reactions. Visual effects were also noted, including dry eye, blurred vision, and “floaters.”

Because patisiran can diminish vitamin A levels in serum, patients should take an oral supplement providing the recommended daily allowance.

Patisiran, manufactured by Alnylam Pharmaceuticals, recently received a positive opinion from Europe’s main drug review committee for hATTR amyloidosis in adults with stage 1 or stage 2 polyneuropathy, and the United Kingdom’s Medicines and Healthcare Products Regulatory Agency decided last week to make it available to hATTR amyloidosis patients before it receives formal marketing authorization.

RNAi technology — also called siRNA for small interfering RNA — uses short nucleic acid strings to interrupt gene translation and expression. Two U.S. geneticists who developed the process won a Nobel Prize in Medicine in 2006, and drug developers have been seeking to exploit it for therapeutic purposes for longer than that.

Contributing writer Judy George provided background material for this report.

2018-08-10T13:53:16-0400
Comments

Accessibility Statement

At MedPage Today, we are committed to ensuring that individuals with disabilities can access all of the content offered by MedPage Today through our website and other properties. If you are having trouble accessing www.medpagetoday.com, MedPageToday's mobile apps, please email legal@ziffdavis.com for assistance. Please put "ADA Inquiry" in the subject line of your email.

Medpage Today

Patisiran Wins Two Firsts With FDA Approval

RNAi drug OK'd to treat polyneuropathy from hereditary transthyretin amyloidosis

MedpageToday

  • by Managing Editor, MedPage Today

WASHINGTON -- The FDA said Friday it had approved patisiran (Onpattro) to treat polyneuropathy associated with hereditary transthyretin (hATTR) amyloidosis, caused by a gene mutation that leads to amyloid deposits in nerves and tissues.

Not only is patisiran the first drug with this indication, it's also the first so-called RNA interference (RNAi) agent to win approval for any condition, the FDA noted.

Formerly known as familial amyloid polyneuropathy, hATTR amyloidosis is a rapidly progressive disease caused by a mutation in the TTR gene that results in the buildup of misfolded transthyretin protein, leading to amyloid deposits in the heart, gastrointestinal tract, and peripheral nerves. Life expectancy of patients is about 3 to 15 years after the onset of neuropathy, less in patients who have cardiomyopathy.

In the phase III APOLLO trial, patisiran slowed peripheral neuropathy progression in patients with hATTR amyloidosis, improving neurological impairment and clinical manifestations by over 18 months.

In that trial, involving 225 patients, those "who received Onpattro had better outcomes on measures of polyneuropathy including muscle strength, sensation (pain, temperature, numbness), reflexes and autonomic symptoms (blood pressure, heart rate, digestion) compared to those receiving the placebo infusions," the FDA noted in its approval announcement. "Onpattro-treated patients also scored better on assessments of walking, nutritional status, and the ability to perform activities of daily living."

Adverse effects seen in the clinical studies included infusion-related reactions, back pain, nausea, abdominal pain, dyspnea, and headache, the FDA said. All patients in the trials were pretreated with acetaminophen, antihistamines, and a corticosteroid to minimize infusion reactions. Visual effects were also noted, including dry eye, blurred vision, and "floaters."

Because patisiran can diminish vitamin A levels in serum, patients should take an oral supplement providing the recommended daily allowance.

Patisiran, manufactured by Alnylam Pharmaceuticals, recently received a positive opinion from Europe's main drug review committee for hATTR amyloidosis in adults with stage 1 or stage 2 polyneuropathy, and the United Kingdom's Medicines and Healthcare Products Regulatory Agency decided last week to make it available to hATTR amyloidosis patients before it receives formal marketing authorization.

RNAi technology -- also called siRNA for small interfering RNA -- uses short nucleic acid strings to interrupt gene translation and expression. Two U.S. geneticists who developed the process won a Nobel Prize in Medicine in 2006, and drug developers have been seeking to exploit it for therapeutic purposes for longer than that.

Contributing writer Judy George provided background material for this report.

2018-08-10T13:53:16-0400
Comments

Accessibility Statement

At MedPage Today, we are committed to ensuring that individuals with disabilities can access all of the content offered by MedPage Today through our website and other properties. If you are having trouble accessing www.medpagetoday.com, MedPageToday's mobile apps, please email legal@ziffdavis.com for assistance. Please put "ADA Inquiry" in the subject line of your email.



Source link

SHARE
Previous articleAlnylam's gene silencing drug wins FDA approval
Next articlePediatric Lupus: Different than in Adults
Dr Irfanullah Khan Born: 15th July,1994 in Khagram,Dir Upper KPK Pakistan. Others names:Doctor Irfo,Peshoo Education:Pharm-D Scholar Graduated from Abasyn University Peshawar. Occupation:Clinical Pharmacist,Doctor,Entrepreneur. Home Town:Dir Upper Height: 6 feet. Website:Iukmedonline.com

LEAVE A REPLY

Please enter your comment!
Please enter your name here